Sectors
PLX
Protalix BioTherapeutics, Inc.
2.33
2 x 2.32
1 x 2.33
bid
ask
-
0.03
1.27%
09:50 AM
timesize
| Ytd | 29.44% | |
| 1y | 47.47% |
2.31
day range
2.37
1.41
52 week range
3.19
| Open | 2.34 | Prev Close | 2.36 | Low | 2.31 | High | 2.37 | Mkt Cap | 190.15M |
| Vol | 26.93K | Avg Vol | 724.14K | EPS | 0.18 | P/E | 12.97 | Forward P/E | 2.79 |
| Beta | N/A | Short Ratio | 22.71 | Inst. Own | 5.20% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 2.15 | 200-d Avg | 2.22 | 1yr Est | 14.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-14 | 2024-09 | 0.06 | 0.03 | -0.03 | -50.00% |
| 2024-08-14 | 2024-06 | 0.02 | -0.03 | -0.05 | -250.00% |
| 2024-05-10 | 2024-03 | 0 | -0.06 | N/A | N/A |
| 2024-03-14 | 2023-12 | -0.03 | -0.07 | -0.04 | -133.33% |
| 2023-11-06 | 2023-09 | -0.07 | -0.04 | 0.03 | 42.86% |
| 2023-08-07 | 2023-06 | -0.04 | 0.21 | 0.25 | 625.00% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2023-11-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2023-10-31 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-03-31 | BASHAN DROR | Chief Executive Officer | 0.00 | Stock Award(Grant) |
| 2023-08-14 | HAYON YAEL | Officer | 0.00 | Stock Award(Grant) |
| 2023-08-14 | NAOS YARON | Officer | 0.00 | Stock Award(Grant) |
| 2024-09-22 | RUBIN EYAL | Chief Financial Officer | 0.00 | Stock Award(Grant) |
| 2023-01-02 | SCHWARTZ AHARON | Director | 174.00K | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Renaissance Technologies, LLC | 955.90K | 1.65M | 1.30% |
| 2024-09-29 | Gsa Capital Partners Llp | 435.21K | 752.92K | 0.59% |
| 2024-09-29 | Millennium Management Llc | 373.76K | 646.60K | 0.51% |
| 2024-09-29 | Stratos Wealth Partners, Ltd. | 270.00K | 467.10K | 0.37% |
| 2024-09-29 | Bridgeway Capital Management, Inc. | 183.79K | 317.96K | 0.25% |
| 2024-09-29 | Blackrock Inc. | 178.78K | 309.30K | 0.24% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Bridgeway Funds Inc-Ultra Small Company Market Fund | 180.00K | 311.40K | 0.24% |
| 2024-10-30 | iShares Micro Cap ETF | 162.70K | 281.46K | 0.22% |
| 2024-09-29 | EQ Advisors Trust-1290 VT Micro Cap Port | 14.97K | 25.89K | 0.02% |
| 2024-09-29 | Northern Small Cap Core Fund | 503.00 | 870.00 | 0.00% |
| 2024-09-29 | John Hancock Var Ins Tr-Total Stock Market Index Tr | 640.00 | 1.11K | 0.00% |
Split
| Split | Date |
|---|---|
| 1 : 10 | 2019-12-20 |
| 0.1 : 1 | 2007-01-03 |